The prognostic value of c‐Kit, K‐ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer
Abstract
BACKGROUND: The prognosis for patients with colorectal cancer (CRC) depends mainly on standard clinicopathologic factors. However, patients with similar disease characteristics exhibit various outcomes, especially in stage II. Therefore, the identification of molecular prognostic markers is needed to predict patient outcomes. METHODS: The authors assessed the prognostic value of c‐Kit (also called cluster of differentiation 117 [CD117] or KIT), cyclooxygenase‐2 (COX‐2), tumor protein 53 (p53), and Kirsten rat sarcoma viral oncogene homolog (K‐ras) aberrations in 90 patients with stage II CRC using immunohistochemistry and molecular techniques. The results were correlated with standard clinicopathologic prognostic factors, overall survival (OS), and disease‐free survival (DFS). RESULTS: COX2 and c‐Kit overexpression was detected in 54.6% and 59.3% of patients, respectively. Overexpression of p53 was detected in 47 patients, including 29 who had mutations, and a unique mutation pattern was detected with 3 hotspots at codons 72, 245, and 273. Overexpression of ras was detected in 44 patients, including 37 who had mutations. On multivariate analysis, c‐Kit overexpression, p53 codon 72 mutations, perforation, and performance status were independent prognostic factors for DFS (P = .054, P = .015, P < .0001, and P = .043, respectively); whereas codon 12 K‐ras mutation, performance status, and perforation were independent prognostic factors for OS (P = .033, P = .006, and P < .0001, respectively). CONCLUSIONS: The current results provide evidence for the prognostic value of c‐Kit overexpression in patients with stage II CRC. The high p53 mutation rate and the unique hotspot in codon 72 have not been reported previously in CRC. This may be related to environmental or racial features that are unique to the studied population. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Prognostic significance of bcl-2 and p53 expression in colorectal carcinomaJournal of Zhejiang University-SCIENCE B, 2005
- American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon CancerJournal of Clinical Oncology, 2004
- Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough?Annals of Oncology, 2003
- Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative StudyJournal of Clinical Oncology, 2003
- Prognostic significance of p53 mutations in colon cancer at the population levelInternational Journal of Cancer, 2002
- Mutations and Allelic Loss of p53 in Primary Tumor DNA From Potentially Cured Patients With Colorectal CarcinomaJournal of Clinical Oncology, 2001
- Guidelines 2000 for Colon and Rectal Cancer SurgeryJNCI: Journal of the National Cancer Institute, 2001
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final ReportAnnals of Internal Medicine, 1995
- The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survivalInternational Journal of Cancer, 1994
- ras GENESAnnual Review of Biochemistry, 1987